Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05486572 · ClinicalTrials.gov registry record · NA
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
A NA study of Cirrhosis and Carcinoma, Hepatocellular, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- NA
- Development phase
- 4,700
- Enrollment target
- 17
- Study locations
NCT05486572 is a NA study of Cirrhosis and Carcinoma, Hepatocellular that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 4,700 participants, below the 90,320-participant average among 53 other Cirrhosis trials with a reported enrollment target (95% lower). The trial reports 17 study locations across 13 states.
The verdict
NCT05486572, a NA study of Cirrhosis and Carcinoma, Hepatocellular, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- NA
- Development phase
- 4,700 participants
- Enrollment target
- 17
- Study locations
Study Summary
The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in patients at high risk of developing HCC. The investigators hypothesize that HCC will be detected at earlier stages, allowing for more curative treatments and resulting in a reduction in HCC-related mortality.
Conditions Studied
Interventions
- OTHER Abbreviated Magnetic Resonance Imaging with serum AFP
- OTHER Abdominal Ultrasound Screening with serum AFP
Study Locations (17)
California
- VA Long Beach Healthcare System, Long Beach, CA - Long Beach
- VA Palo Alto Health Care System, Palo Alto, CA - Palo Alto
- VA Northern California Health Care System, Mather, CA - Sacramento
- VA San Diego Healthcare System, San Diego, CA - San Diego
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA - West Los Angeles
Colorado
- Rocky Mountain Regional VA Medical Center, Aurora, CO - Aurora
Connecticut
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT - West Haven
Florida
- James A. Haley Veterans' Hospital, Tampa, FL - Tampa
Massachusetts
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA - Boston
Michigan
- VA Ann Arbor Healthcare System, Ann Arbor, MI - Ann Arbor
Nebraska
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE - Omaha
New York
- James J. Peters VA Medical Center, Bronx, NY - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,700 participants |
| Start Date | 2023-11-03 |
| Est. Completion | 2031-09-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05486572
The ClinicalTrials.gov registry entry for NCT05486572 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 4,700 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90,320-participant average among 53 other Cirrhosis trials with a reported enrollment target (95% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Abbreviated Magnetic Resonance Imaging with serum AFP is the first listed.
NCT05486572 reports 17 study locations spanning 13 distinct geographic areas - top geographies include California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05486572 about?
NCT05486572 is a clinical study titled "Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI". The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in p...
What is the current status of trial NCT05486572?
This trial is currently recruiting. It is a NA study. The enrollment target is 4,700 participants. The study started on 2023-11-03. Estimated completion is 2031-09-01.
What conditions does trial NCT05486572 study?
This clinical trial studies the following conditions: Cirrhosis, Carcinoma, Hepatocellular.
What interventions are being tested in trial NCT05486572?
The interventions under investigation include: Abbreviated Magnetic Resonance Imaging with serum AFP (OTHER), Abdominal Ultrasound Screening with serum AFP (OTHER).
Who is sponsoring clinical trial NCT05486572?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05486572 being conducted?
This trial has 17 study locations across California, Colorado, Connecticut, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
RECRUITING · NA
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
RECRUITING · NA
-
CirrhosisRx CDS System
RECRUITING · NA
-
Microbiome Modulation With Prebiotics in PTSD and Cirrhosis
RECRUITING · NA
-
Adverse Outcomes and Mortality in Liver Transplant
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.